Anbio Biotechnology
Business
Anbio Biotechnology develops, registers, and commercializes in vitro diagnostic (IVD) products and point‑of‑care medical diagnostic solutions. It offers assays and instruments including lateral flow immunoassays (LFIA), fluorescence immunoassays (FIA), LAMP, RT‑PCR, chemiluminescence immunoassays (ChLIA), and rapid antigen tests for respiratory pathogens. The business is organized around point‑of‑care/OTC, molecular diagnostics, and laboratory diagnostics segments and outsources R&D and manufacturing to third‑party laboratories and suppliers. Anbio sells via direct sales and distributor channels across the European Union, Asia‑Pacific, the Americas and Africa, pursuing regional regulatory approvals (CE/IVDR, LDT/FDA pathways).
Summary from filing dated 2025-04-28
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $8.65M |
| Net income | $6.40M |
| Total assets | $30.24M |
| Total liabilities | $87.8K |
| Stockholders' equity | $30.16M |
| Operating cash flow | $-6.74M |